4 reports of this reaction
1.6% of all SULFACETAMIDE SODIUM, SULFUR reports
#15 most reported adverse reaction
PULMONARY EMBOLISM is the #15 most commonly reported adverse reaction for SULFACETAMIDE SODIUM, SULFUR, manufactured by Aurobindo Pharma Limited. There are 4 FDA adverse event reports linking SULFACETAMIDE SODIUM, SULFUR to PULMONARY EMBOLISM. This represents approximately 1.6% of all 251 adverse event reports for this drug.
Patients taking SULFACETAMIDE SODIUM, SULFUR who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is a less commonly reported adverse event for SULFACETAMIDE SODIUM, SULFUR, but still significant enough to appear in the safety profile.
In addition to pulmonary embolism, the following adverse reactions have been reported for SULFACETAMIDE SODIUM, SULFUR:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 4 FDA reports for SULFACETAMIDE SODIUM, SULFUR. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 1.6% of all adverse event reports for SULFACETAMIDE SODIUM, SULFUR, making it a notable side effect.
If you experience pulmonary embolism while taking SULFACETAMIDE SODIUM, SULFUR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.